Dana Farber Cancer Institute/Pharmacy

Boston, Massachusetts 02215

0 studies enrolling now · 2 studies all time

What they study most

Carcinoma, Non-Small-Cell Lung, Non Small Cell Lung Cancer ALK Positive or ROS1 Positive

Studies at this site

• Expanded Access For Lorlatinib For Patients With Non Small Cell Lung Cancer ALK Positive or ROS1 Positive — NO_LONGER_AVAILABLE
• An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene — Completed